welcome and you, Thank everyone. Tierney
the partnerships; that beginning summarized address those the increased with achieved We At we and XXXX, on AMPYRA executed changes the in I team will we and INBRIJA And our to two those the net will We of in. We trajectory. these Board, guidance made on a and INBRIJA’s our now ex-U.S. dive of leadership additions face goals of the strengthened expenses We sales we generic maintain our I’m detail. balance top commercialization established and right fiscal are in and more important all slide. and goals, happy for review we sheet. Spain discipline. challenges. Germany, bit this our you company’s We in to launched to report of executed minimized and competition,
pay and early overhang. on to due in So in us was approximately for XXXX a That that our sheet. manufacturing do To turn, convertible removed significant Acorda’s million enabled operations regarding $XX million balance which strengthening to $XX that, we Catalent June, stub debt in our net. the sold payment
from credit million We also a $X.X the CARES received Act. tax
XXXX, in mid-XXXX. royalty Acorda financials we on but an expect Biogen FAMPYRA sales expense that as continued royalty accompanying with Now looking has in this will revenue ex-U.S. we appear from to revert XXXX, as have the revert we to our the this had the of that double-digit end to Note to ahead, the expect partners Acorda. in around health and to with we that whom middle care sold it we to royalty back – on to stream obligation royalty payments of passed whom year
sales to We revenue also INBRIJA from in of expect XXXX. receive ex-U.S.
discipline, on Regarding our they in revenue sale by were expense what addition, the expect expenses end by and to Based manufacturing headcount will in in expenses. implemented we reductions reduced aim the basis cash operations operating company’s flow other And annual also and rate that fiscal to over our million our our about in the on we XXXX of we of reduce XXXX $XX XXXX. neutral OpEx be on a XXXX. be positive cash projections, run flow operating and
Spain million we $X.X with in of net selling in launch market agreement to supply a product to for Germany an Germany. the based Europe, in ESTEVE Spain. in mid-XXXX That’s in commercialize world. will upfront double-digit largest additional ESTEVE of we well also receive in as Acorda Now with payment, ESTEVE agreement as a payments to significant received the INBRIJA early the November, the expects pharmaceutical largest in in executed an fourth sales. in XXXX. percent INBRIJA price commercialize INBRIJA announced And and also milestone on the
Europe actively territories discussions rest INBRIJA other with parties and to world. in additional quite the We’re in commercialize in of also the
build January joined extensive November. Mike biopharma General discipline Commission. from the Belloff as while CFO the to as moved is Access experienced going of senior at to notwithstanding of several John role Sales and Clem, organization CEO Chief to as was continue shareholder Lauren Gesser Commercial has held in Counsel of biotech and had build Sabella the level our And is I is of November. biotech has Varian Neil Acorda’s including to forward. He this indicative changes, Operating Acorda our at appointed current of has and our will and fiscal Officer. has maintain this Market executive Officer our legal veteran. the and was that enhancing our Chief efficiency and to companies Mike he’s finance named at experience an Acorda Neil the held in Officer, year. to Acorda companies that additions Securities such company’s talent Exchange served also high has boards. as Celgene CFO attract challenges leadership and ability senior shareholder served value. Commercial to in large increase experience EVP positions value the to Moving to who note John and opportunity He Chief of small ability roles both also Allergan. Kerry Board on both joined
our full a So That’s increase million. XXXX performance, moving INBRIJA to commercial XX% revenue for XXXX. net $XX.X the was year over
full of AMPYRA fourth was We achieved million. revenue million. our XXXX for over QX increases during AMPYRA XXXX. these range in see For $XX.X was for top impact trajectory, guidance the the $XX.X encouraged in a were the that’s ongoing COVID-XX the net business and fourth net net the year was quarter, in year. our revenue quarter, We generic sales increase on $XX.X revenue the of particularly light XX% of face the And to competition. continuing million, INBRIJA’s of for
more INBRIJA. bit detail a Moving on
a indicated inhaled doses with are between is scheduled people regularly INBRIJA experience Parkinson’s many address medication. It’s what to or the return of periods their of OFF in levodopa. As that reminder, called symptoms,
decline with did I as that. visits to some ways. offices In-person declined of pandemic continue to XXXX of initial XXXX, after waxed with patient return in headwinds office manifested visits the Omicron the in wave. most and from overall to number give in a More launch to on those COVID, levels. have precipitous you each have but wave levels continued mentioned, new I’ll It pre-pandemic Now for pose patients the color successive the recently waned and
programs. not patient or in to visits during significantly OFF accepting than that programs Until on recently, speaker them with in-person they’re the in for stopped what address about practices disease, found able to many people periods. their need very their their to to is in-person we their doctor pre-pandemic activity many now. hold in by true that outside salespeople Parkinson’s we thus, likely person, report whether remain better. the and remains back treat therapy addition, office, physician INBRIJA lower group. substantially to to more their salespeople educating ramp And physician they still group have person, In related were that very effective And levels, it’s although it and marketing pandemic everything are we patients, up can speaker in calling beginning a the works less high-risk learned or they having where physicians, particular, with actual were in of reduced an because homes of Also, a we is programs,
activities, at TV going usual than rather what outdoor that’s home, watching do. sitting lot to your a you’re If you’re
exercise to to So as part subsides. Parkinson’s accelerate significant as we and resume activity, I the activity encouraged that pandemic the from, particularly people good and they up X Exercise news of levels of manage looking that INBRIJA Hopefully, for are let’s Parkinson’s think ways now. hibernation forth. exercise. are with call years launch their activity reemerge to as are on so finally and key these here happening We seeing the that largely occurs that are is one become people eager an to opportunities with the reverse as and to expect it, of see we the the factors and that can that PD of catch them last important and be therefore
compared XXXX. COVID the to headwinds, see able metrics, INBRIJA adapt means Here, and and our in despite continue some to otherwise team through additional digital creatively again, was we growth to
we XXXX with over a in increase sales fourth in growth XX% quarter As versus annual XXXX the a in XXXX. saw I XX% fourth quarter net mentioned,
unusually would of large that we factors the due a specialty the mind, that sales moving or pharmacies of one. time in to in all quarter. that sales transition, largely even quarter excess and normally related single bear And saw to more merging fourth several than see into ordering outsized during Now from fourth had we our at XXXX
because also follow by one the cartons here, cartons I X.X in a that We of INBRIJA growth. can a is get most had cartons demand organic from that we increase And X.X. to actually anywhere XX% number think up XXXX. of number Note we closely important the patients of from in in X the total went patients actual That’s X measured saw to reflects most average accurately prescriptions receive. increase number QX per prescription prescription. That over single XXXX, the a XX% that in most the
you were pleased curve look XXXX. X to in $X for XXXX the were down continuing same, XXXX essentially overall flatten. approximately you And maybe to quarter-over-quarter. so if AMPYRA, part we They sales that to to But see XX% the the next. quarter of stabilized see were sales Moving net here, over million or from by
to curve revenue that net to seeing that the the is has that stabilize. durability We while of will a flat that decrease over during continue erosion sale begun to we’re rate – of believe stabilize due will the relatively So the or expect the we there believe we product And continue has time year. to over to was begun number factors. and decrease time, be
to there. the have maintained sales and product, call education. support specialists. continuing remain is They the loyalty loyal our physicians field provided we brand the support earns and to First, patients team MS relationships on strong We that
Program First And provide patients, of continue their reimbursement for and mitigate to insured example, our co-pay commercially continue support. commercially Step we for which months insured then first cost We AMPYRA out-of-pocket in provide, physician X and their free. get patients we to
and Gesser, of will this XXXX Mike? to going an I’m turn the financials who Now Mike provide CFO, you with our guidance. to overview over
